Wells Fargo analyst Eva Fortea Verdejo raised the firm’s price target on Zymeworks (ZYME) to $25 from $17 based on recent news, while keeping an Equal Weight rating on the shares. The firm thinks there is value in the partnership approach, but is cautious on the royalty-driven strategy beyond zani until it gets more clarity.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks price target raised to $40 from $30 at Stifel
- Zymeworks’ Promising Phase 3 Results Drive Buy Rating for HER2-Positive Cancer Treatment
- Zymeworks Appoints Scott Platshon as Acting CIO
- Zymeworks price target raised to $32 from $26 at H.C. Wainwright
- Zymeworks announces new $125M share repurchase plan